ERBB2 and cancer: The three major subtypes, namely, hormone-receptor-positive/HER2-negative cancers (70%), HER2-positive cancers (15–20%), and triple-negative cancers (15%), vary in prognosis but offer distinctive options for targeted or systemic treatment [32].